About Quantified Imaging

Quantified Imaging develops non-invasive MRI diagnostic tools utilizing Arterial Spin Labeling (ASL) and Chemical Exchange Saturation Transfer (CEST) technologies to enhance the understanding of neurodegeneration and oncology. Their solutions aim to improve diagnostic accuracy and reduce scan times, thereby accelerating clinical trials and research workflows.

```xml <problem> Conventional MRI techniques for assessing neurodegeneration and oncology often require contrast agents or tracers, which can be invasive or carry risks for certain patient populations. Traditional methods may also suffer from limitations in sensitivity and specificity, hindering early and accurate diagnosis. </problem> <solution> Quantified Imaging develops non-invasive MRI diagnostic tools based on Arterial Spin Labeling (ASL) and Chemical Exchange Saturation Transfer (CEST) technologies. These techniques enable the measurement of perfusion and molecular changes in the brain without the need for contrast agents or radioactive exposure. By applying variational Bayesian inference machine learning technology, the company's solutions aim to improve diagnostic accuracy, reduce scan times, and simplify clinical workflows. The technology facilitates a better understanding of disease progression and accelerates clinical trials in neurodegeneration and oncology. </solution> <features> - Non-invasive perfusion measurement using Arterial Spin Labeling (ASL) MRI. - Tracer-free molecular imaging with Chemical Exchange Saturation Transfer (CEST) MRI. - Gold-standard variational Bayesian inference machine learning for image analysis. - Streamlined clinical workflows for improved efficiency. - Enhanced diagnostic accuracy for early detection of neurodegeneration and oncology. - Applications in dementia and traumatic brain injury diagnosis. </features> <target_audience> The primary target audience includes clinical radiologists, neurologists, oncologists, and researchers focused on neurodegeneration and oncology, as well as pharmaceutical companies conducting clinical trials. </target_audience> ```

What does Quantified Imaging do?

Where is Quantified Imaging located?

Quantified Imaging is based in London, United Kingdom.

When was Quantified Imaging founded?

Quantified Imaging was founded in 2023.

Location

London, United Kingdom

Founded

2023

Employees

7 employees

Major Investors

Innovate UK

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Quantified Imaging

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

quantified-imaging.com 300+

Crunchbase

Founded 2023 – London, United Kingdom

Funding

Major Investors

Innovate UK

Team (5+)

No team information available.

Company Description

Problem

Conventional MRI techniques for assessing neurodegeneration and oncology often require contrast agents or tracers, which can be invasive or carry risks for certain patient populations. Traditional methods may also suffer from limitations in sensitivity and specificity, hindering early and accurate diagnosis.

Solution

Quantified Imaging develops non-invasive MRI diagnostic tools based on Arterial Spin Labeling (ASL) and Chemical Exchange Saturation Transfer (CEST) technologies. These techniques enable the measurement of perfusion and molecular changes in the brain without the need for contrast agents or radioactive exposure. By applying variational Bayesian inference machine learning technology, the company's solutions aim to improve diagnostic accuracy, reduce scan times, and simplify clinical workflows. The technology facilitates a better understanding of disease progression and accelerates clinical trials in neurodegeneration and oncology.

Features

Non-invasive perfusion measurement using Arterial Spin Labeling (ASL) MRI.

Tracer-free molecular imaging with Chemical Exchange Saturation Transfer (CEST) MRI.

Gold-standard variational Bayesian inference machine learning for image analysis.

Streamlined clinical workflows for improved efficiency.

Enhanced diagnostic accuracy for early detection of neurodegeneration and oncology.

Applications in dementia and traumatic brain injury diagnosis.

Target Audience

The primary target audience includes clinical radiologists, neurologists, oncologists, and researchers focused on neurodegeneration and oncology, as well as pharmaceutical companies conducting clinical trials.